Skip to content

XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

Tag: Vaccine

October 10, 2026

FDA Approves Updated Nuvaxovid Vaccine for the 2026-2027 Season

NASDAQ: $NVAX Staying Ahead of COVID-19: The Latest Vaccine Update The landscape of COVID-19 vaccination continues to evolve to provide the most effective protection against circulating variants. Recently, the U.S. Food and Drug Administration (FDA) took a significant step by approving the XBB.1.5-adapted Nuvaxovid vaccine for the upcoming 2026-2027 vaccination season. What You Need to…

FDA Acceptance

$NVAX, COVID-19, fda, FDA Approval, Immunization, Novavax, Inc., Nuvaxovid, Vaccine
September 2, 2026

Updated COVID-19 Protection: FDA Approves New Pfizer-BioNTech Comirnaty Vaccine

NYSE: $PFE A New Development in COVID-19 Prevention As we continue to navigate the evolving landscape of respiratory health, the U.S. Food and Drug Administration (FDA) has taken a significant step forward. Pfizer and BioNTech have officially received FDA approval for their updated Comirnaty COVID-19 vaccine, specifically adapted to target more recent circulating variants. What…

FDA Acceptance

$PFE, BioNTech, COVID-19, fda, FDA Approval, pfizer, Vaccine

© XBioReport.com

Disclaimer: This site is for information only. Not investment advice.

Subscribe For A Premium Report To Maximize Your Returns

The FREE bio tech stock catalyst report ONLY includes companies with catalysts within the current week. Often, this may not be enough time to capture the pre-catalyst stock price movements. For MAX RETURNS. Subscribe to a premium report type below and you will receive reports with a longer outlook, allowing you to discover earlier entries to be positioned before a price move happens. Don’t miss out, maximize your return potential!

Choose your outlook window (each priced accordingly)

Get FREE Biotech Stock Catalyst Reports

Email